1-4 of 4
Angelo De Blasio
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Azacitidine In The Treatment Of Ph- Myeloproliferative Neoplasms In Blastic Phase: The Experience Of Gruppo Laziale For The Study Of Ph- SMPC

Alessandro Andriani, Roberto Latagliata, MD, Maria Teresa Voso, M.D., Nicoletta Villivà, Fabrizio Ciccone, Cristina Andrizzi, MD, Cinzia De Gregoris, Francesco Buccisano, MD, Angelo De Blasio, Barbara Anaclerico, MD, Giuseppe Avvisati, MD, PhD, Antonino Bagnato, MD, Michele Cedrone, Giuseppe Cimino, MD, Ignazio Majolino, Prof, Enrico Montefusco, Antonio Spadea, Giuliana Alimena, Marco Montanaro
Journal: Blood
Blood (2013) 122 (21): 5270.
https://doi.org/10.1182/blood.V122.21.5270.5270
Published: 2013
Journal Articles

An open-label, pilot study of fludarabine, cyclophosphamide, and alemtuzumab in relapsed/refractory patients with B-cell chronic lymphocytic leukemia

Clinical Trials & Observations
Marco Montillo, Alessandra Tedeschi, Valeria Belsito Petrizzi, Francesca Ricci, Monica Crugnola, Mauro Spriano, Pierangelo Spedini, Fiorella Ilariucci, Lilj Uziel, Immacolata Attolico, Eleonora Vismara, Angelo De Blasio, Alfonso Zaccaria, Enrica Morra
Journal: Blood
Blood (2011) 118 (15): 4079–4085.
https://doi.org/10.1182/blood-2011-05-351833
Published: 2011
Journal Articles

Fludarabine, Cyclophosphamide, and Alemtuzumab (FCC) In Relapsed/Refractory Patients with B-Cell Chronic Lymphocytic Leukemia (CLL): Final Report of the Italian Study

Marco Montillo, MD, Alessandra Tedeschi, Francesca Ricci, Alfonso Zaccaria, Monica Crugnola, Mauro Spriano, PierAngelo Spedini, Fiorella Ilariucci, Lilj Uziel, Immacolata Attolico, Angelo De Blasio, Eleonora Vismara, Enrica Morra, Valeria Belsito Petrizzi
Journal: Blood
Blood (2010) 116 (21): 1384.
https://doi.org/10.1182/blood.V116.21.1384.1384
Published: 2010
Journal Articles

Combined Fludarabine, Cyclophosphamide, and Alemtuzumab (FCC), an Active Regimen for Treated Patients with Chronic Lymphocytic Leukemia (CLL).

Marco Montillo, MD, Sara Miqueleiz, MD, Alessandra Tedeschi, MD, Francesca Ricci, MD, Eleonora Vismara, MD, Denis Ciapanna, MD, Valeria Belsito Petrizzi, MD, Monica Crugnola, MD, Mauro Spriano, MD, Lilj Uziel, MD, Angelo De Blasio, MD, Pierangelo Spedini, PhD, Enrica Morra, MD
Journal: Blood
Blood (2007) 110 (11): 3133.
https://doi.org/10.1182/blood.V110.11.3133.3133
Published: 2007